At the time of data cutoff ( May 5 , 2014 ) , 98 ( 74 % ) patients had disease progression in the gefitinib group compared with 107 ( 81 % ) in the placebo group ( hazard ratio 086 , 95 % CI 065-113 ; p = 027 ; median progression-free survival 54 months in both groups [ 95 % CI 45-57 in the gefitinib group and 46-55 in the placebo group ] ) .